Evidence map›Paper›PMID 25012418›Full record

Trial reportJournal of affective disorders2014

Neurocognitive predictors of antidepressant clinical response.

Gerard E Bruder, Jorge E Alvarenga, Daniel Alschuler, Karen Abraham, John G Keilp, David J Hellerstein, Jonathan W Stewart, Patrick J McGrath

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of affective disorders, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Profiling the structural determinants of aminoketone derivatives as hNET and hDAT reuptake inhibitors by field-based QSAR based on molecular docking.Technology and health care : official journal of the European Society for Engineering and Medicine · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Gerard E BruderDepartment of Psychiatry, Columbia University College of Physicians & Surgeons, New York, NY, USA; Division of Cognitive Neuroscience, New York State Psychiatric Institute, New York, NY, USA. Electronic address: bruderg@nyspi.columbia.edu.
Jorge E AlvarengaDivision of Cognitive Neuroscience, New York State Psychiatric Institute, New York, NY, USA.
Daniel AlschulerDivision of Cognitive Neuroscience, New York State Psychiatric Institute, New York, NY, USA.
Karen AbrahamDivision of Cognitive Neuroscience, New York State Psychiatric Institute, New York, NY, USA.
John G KeilpDepartment of Psychiatry, Columbia University College of Physicians & Surgeons, New York, NY, USA; Division of Molecular Imaging & Neuropathology, New York State Psychiatric Institute, New York, NY, USA.
David J HellersteinDepartment of Psychiatry, Columbia University College of Physicians & Surgeons, New York, NY, USA; Depression Evaluation Service, New York State Psychiatric Institute, New York, NY, USA.
Jonathan W StewartDepartment of Psychiatry, Columbia University College of Physicians & Surgeons, New York, NY, USA; Depression Evaluation Service, New York State Psychiatric Institute, New York, NY, USA.
Patrick J McGrathDepartment of Psychiatry, Columbia University College of Physicians & Surgeons, New York, NY, USA; Depression Evaluation Service, New York State Psychiatric Institute, New York, NY, USA.
Columbia University · USNew York Psychoanalytic Society and Institute · USNew York State Psychiatric Institute

Funding

BEHAVIORAL, ERP AND RCBF ASYMMETRY IN AFFECTIVE DISORDERR01MH036295 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI BRUDER, GERARD E · 1985 to 2012
$3.7M
Combining Antidepressants to Hasten Remission from DepressionR01MH076961 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI STEWART, JONATHAN W · 2007 to 2010
$1.3M
NIMH NIH HHS MH076961NIMH NIH HHS MH36295NIMH NIH HHS R01 MH036295NIMH NIH HHS R01 MH076961
6 · The paper itself

Abstract

backgroundExecutive dysfunction and psychomotor slowing in depressed patients have been associated with poor antidepressant clinical response, but little is known about the value of neurocognitive tests for differential prediction of response.

methodsThis report presents new findings for 70 depressed patients tested on neurocogntive tests before receiving treatment with a SSRI (escitalopram or citalopram), NDRI (bupropion) or dual mechanism therapy including a serotonergic agent, and for 57 healthy controls.

resultsAs predicted from previous research, patients who did not respond to a SSRI or dual therapy showed poorer word fluency than responders, whereas this was not seen for patients treated with bupropion alone. Longer choice reaction time (RT) was also found in nonresponders to a SSRI or dual therapy, but the opposite trend was seen for bupropion. Using a combined index of word fluency and RT (with normative performance as a cutoff) yielded differential predictions of response. Equal to or above normal performance predicted good response to a SSRI or dual therapy, with high positive predictive value (90%) and specificity (78%) but lower sensitivity (53%). In contrast, less than normal performance predicted good response to bupropion alone (positive predictive value=82%; specificity=67%; sensitivity=90%). LIMITATIONS: Relatively small sample size, no placebo control, and combining across SSRI alone and dual treatments.

conclusionsAlthough findings are preliminary due to small sample size, brief tests of word fluency and psychomotor speed may help identify depressed patients who are unresponsive to a serotonergic agent, but who may respond to bupropion alone.

Indexed as

AdultAntidepressive Agents, Second-GenerationBupropionCase-Control StudiesCitalopramDepressive DisorderDouble-Blind MethodFemaleHumansMaleMiddle AgedSelective Serotonin Reuptake InhibitorsTreatment OutcomeAntidepressive Agents, Second-GenerationBupropionCitalopramSelective Serotonin Reuptake InhibitorsAntidepressantsDepressionNeurocognitive testsPsychomotor speedTreatment response

Identifiers

PMID25012418
PMCPMC4518557
OpenAlexW2122310301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.